Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.54 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | LSS | P48449 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659509 | 0.86 | HRH3 (0.82) | HRH3ALDH1A1TSHRTAAR1NOS3 | |
| SCHEMBL12803574 | 0.79 | HRH3 (0.64) | HRH3ALDH1A1TSHRTAAR1NOS3 | |
| SCHEMBL12679031 | 0.78 | HRH3 (1.00) | HRH3ALDH1A1TSHRTAAR1NOS3 | |
| SCHEMBL12374 | 0.76 | HRH3 (0.67) | HRH3ALDH1A1TSHRTAAR1NOS3 | |
| SCHEMBL10050868 | 0.76 | HRH3 (0.67) | HRH3ALDH1A1TSHRTAAR1NOS3 | |
| SCHEMBL11312980 | 0.75 | HRH3 (0.65) | HRH3ALDH1A1TSHRTAAR1NOS3 | |
| Phosphine SCHEMBL25337730 | 0.74 | HRH3 (0.64) | HRH3ALDH1A1TSHRTAAR1NOS3 | |
| SCHEMBL5126585 | 0.74 | HRH3 (0.64) | HRH3ALDH1A1TSHRTAAR1NOS3 | |
| SCHEMBL19206134 | 0.74 | HRH3 (0.64) | HRH3ALDH1A1TSHRTAAR1NOS3 | |
| Hydrochloric Acid SCHEMBL21821247 | 0.74 | HRH3 (0.64) | HRH3ALDH1A1TSHRTAAR1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3049072-A1 | SYNTHESIS OF DELTA 12-PGJ3 AND RELATED COMPOUNDS | William Marsh Rice University (US) | 2016-08-03 | — | — | EP | claimed |
| WO-2015048268-A1 | SYNTHESIS OF DELTA 12-PGJ3 AND RELATED COMPOUNDS | WILLIAM MARSH RICE UNIVERSITY (US) | 2015-04-02 | — | — | WO | claimed |
| US-20160318862-A1 | SYNTHESIS OF DELTA 12-PGJ3 AND RELATED COMPOUNDS | WILLIAM MARSH RICE UNIVERSITY (US) | 2016-11-03 | — | — | US | disclosed |
| EP-3049072-A1 | SYNTHESIS OF DELTA 12-PGJ3 AND RELATED COMPOUNDS | William Marsh Rice University (US) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015048268-A1 | SYNTHESIS OF DELTA 12-PGJ3 AND RELATED COMPOUNDS | WILLIAM MARSH RICE UNIVERSITY (US) | 2015-04-02 | — | — | WO | disclosed |
| US-20050261164-A1 | Remedy for urinary frequency and urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1532978-A1 | REMEDY FOR URINARY FREQUENCY AND URINARY INCONTINENCE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
| US-6627714-B2 | Copolymerizing ethylene and dicyclopentadiene or tricyclopentadiene, and cyclic olefin in presence of metallocene catalyst to produce copolymer | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2003-09-30 | — | — | US | disclosed |
| US-20020058767-A1 | Method for producing an olefin type copolymer having a cyclic structure | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2002-05-16 | — | — | US | disclosed |
| EP-1205497-A2 | Method for producing an olefin type copolymer having a cyclic structure | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-6369110-B1 | PROPHYLACTIC AGENT FOR DISEASES CAUSED BY THE ACCELERATION OF THE SODIUM/PROTON EXCHANGE TRANSPORT SYSTEM | SUMITOMO PHARMACEUTICALS COMPANY (JP) | 2002-04-09 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0803501-B1 | Substituted guanidine derivatives and their use as Na+/H+ exchange inhibitors | SUMITOMO PHARMA (JP) | 2000-07-05 | — | — | EP | disclosed |
| US-5977100-A | Substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5834454-A | TREATMENT OF ANGINA, ISCHEMIA, ARRHYTHMIA | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5814654-A | TREATMENT OF HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS, ORGAN DISORDERS ASSOCIATED WITH ISCHEMIA, CEREBRO-ISCHEMIC DISORDERS, CELL PROLIFERATION, ENDOTHELIAL CELL INJURY | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-09-29 | — | — | US | disclosed |
| EP-0803501-A1 | Substituted guanidine derivatives and their use as Na+/H+ exchange inhibitors | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1997-10-29 | — | — | EP | disclosed |
| EP-0787728-A1 | Substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1997-08-06 | — | — | EP | disclosed |
| CN-1136038-A | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICS K K (JP) | 1996-11-20 | — | — | CN | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261164-A1 | Remedy for urinary frequency and urinary incontinence | SLC14A1, SLC26A4, SLC6A12 | HRH3 597/4885ALDH1A1 366/4885TSHR 4389/4885 |
| US-20160318862-A1 | SYNTHESIS OF DELTA 12-PGJ3 AND RELATED COMPOUNDS | DGKZ, DGKG, DNAJA3 | HRH3 4586/4885ALDH1A1 3849/4885TSHR 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.